Transtorno de deficit da atenção com hiperatividade em crianças

Referências

Principais artigos

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.

World Health Organization. ICD-11 International statistical classification of diseases and related health problems, 11th revision. Geneva: WHO; 2022.Texto completo

Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019 Oct;144(4):e20192528.Texto completo  Resumo

Artigos de referência

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.

2. World Health Organization. ICD-11 International statistical classification of diseases and related health problems, 11th revision. Geneva: WHO; 2022.Texto completo

3. Schonwald A, Lechner E. Attention deficit/hyperactivity disorder: complexities and controversies. Curr Opin Pediatr. 2006 Apr;18(2):189-95. Resumo

4. Barkley RA. Attention deficit hyperactivity disorder: a clinical handbook, 3rd ed. New York: Guilford; 2005.

5. Faraone SV, Biederman J, Jetton JG, et al. Attention deficit disorder and conduct disorder: longitudinal evidence for a familial subtype. Psychol Med. 1997 Mar;27(2):291-300. Resumo

6. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1997 Jan;36(1):21-9. Resumo

7. Milberger S, Biederman J, Faraone SV, et al. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997 Jan;36(1):37-44. Resumo

8. Faraone SV, Biederman J. Do attention deficit hyperactivity disorder and major depression share familial risk factors? J Nerv Ment Dis. 1997 Sep;185(9):533-41. Resumo

9. Biederman J, Faraone S, Mick E, et al. Attention-deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc Psychiatry. 1996 Aug;35(8):997-1008. Resumo

10. Spencer TJ, Biederman MD, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol. 2007 Aug;32(8):631-42. Resumo

11. Pliszka SR, Carlson CL, Swanson JM. ADHD with comorbid disorders: clinical assessment and management. New York, NY: Guilford; 1999.

12. Centers for Disease Control and Prevention. Key findings: trends in the parent-report of health care provider-diagnosis and medication treatment for ADHD: United States, 2003-2011. Feb 2017 [internet publication].Texto completo

13. Bloom B, Cohen RA, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2010. Vital Health Stat 10. 2011 Dec;250:1-80. Resumo

14. Biederman J, Faraone SV. The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives. Psychiatr Clin North Am. 2004 Jun;27(2):225-32. Resumo

15. Sayal K, Prasad V, Daley D, et al. ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatry. 2018 Feb;5(2):175-86. Resumo

16. Cuffe SP, Moore CG, McKeown RE. Prevalence and correlates of ADHD symptoms in the National Health Interview Survey. J Atten Disord. 2005 Nov;9(2):392-401. Resumo

17. Epstein JN, Willoughby M, Valencia EY, et al. The role of children's ethnicity in the relationship between teacher ratings of attention-deficit/hyperactivity disorder and observed classroom behavior. J Consult Clin Psychol. 2005 Jun;73(3):424-34. Resumo

18. Langley K, Holmans PA, van den Bree MB, et al. Effects of low birth weight, maternal smoking in pregnancy and social class on the phenotypic manifestation of attention deficit hyperactivity disorder and associated antisocial behavior: investigation in a clinical sample. BMC Psychiatry. 2007 Jun 20;7:26.Texto completo  Resumo

19. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1313-23. Resumo

20. Waldman ID, Gizer IR. The genetics of attention deficit hyperactivity disorder. Clin Psychol Rev. 2006 Aug;26(4):396-432. Resumo

21. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):894-921. Resumo

22. Thapar A, O'Donovan MC, Owen MJ. The genetics of attention deficit hyperactivity disorder. Hum Mol Genet. 2005 Oct 15;14 Spec No 2:R275-82.Texto completo  Resumo

23. Groen-Blokhuis MM, Middeldorp CM, van Beijsterveldt CE, et al. Evidence for a causal association of low birth weight and attention problems. J Am Acad Child Adolesc Psychiatry. 2011 Dec;50(12):1247-54. Resumo

24. Sourander A, Sucksdorff M, Chudal R, et al. Prenatal cotinine levels and ADHD among offspring. Pediatrics. 2019 Mar;143(3):e20183144.Texto completo  Resumo

25. Lahat E, Heyman E, Livne A, et al. Iron deficiency in children with attention deficit hyperactivity disorder. Isr Med Assoc J. 2011 Sep;13(9):530-3. Resumo

26. Froehlich TE, Anixt JS, Loe IM, et al. Update on environmental risk factors for attention-deficit/hyperactivity disorder. Curr Psychiatry Rep. 2011 Sep;13(9):333-44. Resumo

27. Man KK, Chan EW, Ip P, et al. Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. BMJ. 2017 May 31;357:j2350.Texto completo  Resumo

28. Greenhill LL. Stimulant medication treatment of children with attention deficit hyperactivity disorder. In: Jensen PS, Cooper JR, eds. Attention deficit hyperactivity disorder: state of science. best practices. Kingston, NH: Civic Research Institute 2002:9-1-9-27.

29. Wilens TE. Mechanism of action of agents used in attention deficit/hyperactivity disorder. J Clin Psychiatry. 2006;67 Suppl 8:32-8. Resumo

30. Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1397-409. Resumo

31. Sengupta SM, Grizenko N, Thakur GA, et al. Differential association between the norepinephrine transporter gene and ADHD: role of sex and subtype. J Psychiatry Neurosci. 2012 Feb;37(2):129-37.Texto completo  Resumo

32. Elia J, Glessner JT, Wang K, et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet. 2011 Dec 4;44(1):78-84. Resumo

33. Wargelius HL, Malmberg K, Larsson JO, et al. Associations of MAOA-VNTR or 5HTT-LPR alleles with attention-deficit hyperactivity disorder symptoms are moderated by platelet monoamine oxidase B activity. Psychiatr Genet. 2012 Feb;22(1):42-5. Resumo

34. Cortese S. The neurobiology and genetics of attention-deficit/hyperactivity disorder (ADHD): what every clinician should know. Eur J Paediatr Neurol. 2012 Sep;16(5):422-33. Resumo

35. Willcutt EG, Doyle AE, Nigg JT, et al. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry. 2005 Jun 1;57(11):1336-46. Resumo

36. Valera EM, Faraone SV, Murray KE, et al. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007 Jun 15;61(12):1361-9. Resumo

37. Duerden EG, Tannock R, Dockstader C. Altered cortical morphology in sensorimotor processing regions in adolescents and adults with attention-deficit/hyperactivity disorder. Brain Res. 2012 Mar 22;1445:82-91. Resumo

38. Nakao T, Radua J, Rubia K, et al. Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. Am J Psychiatry. 2011 Nov;168(11):1154-63. Resumo

39. Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. Biol Psychiatry. 2005 Jun 1;57(11):1273-84. Resumo

40. Mills KL, Bathula D, Dias TG, et al. Altered cortico-striatal-thalamic connectivity in relation to spatial working memory capacity in children with ADHD. Front Psychiatry. 2012 Jan 25;3:2.Texto completo  Resumo

41. Tomasi D, Volkow ND. Abnormal functional connectivity in children with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2012 Mar 1;71(5):443-50. Resumo

42. Cortese S, Castellanos FX. Neuroimaging of attention-deficit/hyperactivity disorder: current neuroscience-informed perspectives for clinicians. Curr Psychiatry Rep. 2012 Oct;14(5):568-78. Resumo

43. Hoogman M, Bralten J, Hibar DP, et al. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. Lancet Psychiatry. 2017 Apr;4(4):310-9.Texto completo  Resumo

44. Chen L, Hu X, Ouyang L, et al. A systematic review and meta-analysis of tract-based spatial statistics studies regarding attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev. 2016 Sep;68:838-47. Resumo

45. Szatmari P, Saigal S, Rosenbaum P, et al. Psychiatric disorders at five years among children with birth weights less than 1000g: a regional perspective. Dev Med Child Neurol. 1990 Nov;32(11):954-62. Resumo

46. Mick E, Biederman J, Prince J, et al. Impact of low birth weight on attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2002 Feb;23(1):16-22. Resumo

47. Dunn DW, Bourgeois BFD. Learning disabilities and ADHD in children with epilepsy. In: Duchowny M, Cross JH, Arzimanoglou A, eds. Pediatric epilepsy. New York, NY: McGraw Hill Medical; 2013:323-9.

48. Masur D, Shinnar S, Cnaan A, et al; Childhood Absence Epilepsy Study Group. Pretreatment cognitive deficits and treatment effects on attention in childhood absence epilepsy. Neurology. 2013 Oct 29;81(18):1572-80.Texto completo  Resumo

49. Rodriguez A, Bohlin G. Are maternal smoking and stress during pregnancy related to ADHD symptoms in children? J Child Psychol Psychiatry. 2005 Mar;26(3):246-54. Resumo

50. Rutter M, Cox A, Tupling C, et al. Attainment and adjustment in two geographical areas. 1 - The prevalence of psychiatric disorders. Br J Psychiatry. 1975 Jun;126:493-509. Resumo

51. Biederman J, Milberger S, Faraone SV, et al. Family-environment risk factors for attention-deficit hyperactivity disorder. A test of Rutter's indicators of adversity. Arch Gen Psychiatry. 1995 Jun;52(6):464-70. Resumo

52. Biederman J, Faraone SV, Monuteaux MC. Differential effect of environmental adversity by gender: Rutter's index of adversity in a sample of boys and girls with and without ADHD. Am J Psychiatry. 2002 Sep;159(9):1556-62.Texto completo  Resumo

53. Braun JM, Kahn RS, Froehlich T, et al. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect. 2006 Dec;114(12):1904-9.Texto completo  Resumo

54. Max JE, Arndt S, Castillo CS, et al. Attention-deficit hyperactivity disorder symptomatology after traumatic brain injury: a prospective study. J Am Acad Child Adolesc Psychiatry. 1998 Aug;37(8):841-7. Resumo

55. Kreppner JM, O'Connor TG, Rutter M. Can inattention/overactivity be an institutional deprivation syndrome? J Abnorm Child Psychol. 2001 Dec;29(6):513-28. Resumo

56. Cortese S, Angriman M, Lecendreux M, et al. Iron and attention deficit/hyperactivity disorder: what is the empirical evidence so far? A systematic review of the literature. Expert Rev Neurother. 2012 Oct;12(10):1227-40. Resumo

57. Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2011 Oct;50(10):991-1000. Resumo

58. Gillies D, Sinn JKH, Lad SS, et al. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2012 Jul 11;(7):CD007986.Texto completo  Resumo

59. Chang JP, Su KP, Mondelli V, et al. Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: a systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacology. 2018 Feb;43(3):534-45.Texto completo  Resumo

60. Pineda DA, Puerta IC, Aguirre DC, et al. The role of neuropsychological tests in the diagnosis of attention deficit hyperactivity disorder. Pediatr Neurol. 2007 Jun;36(6):373-81. Resumo

61. Weiler MD, Bernstein JH, Bellinger DC, et al. Processing speed in children with attention deficit/hyperactivity disorder, inattentive type. Child Neuropsychol. 2000 Sep;6(3):218-34. Resumo

62. de Boo GM, Prins PJ. Social incompetence in children with ADHD: possible moderators and mediators in social-skills training. Clin Psychol Rev. 2007 Jan;27(1):78-97. Resumo

63. Chang LY, Wang MY, Tsai PS. Diagnostic accuracy of rating scales for attention-deficit/hyperactivity disorder: a meta-analysis. Pediatrics. 2016 Mar;137(3):e20152749. Resumo

64. Steiner H, Remsing L; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jan;46(1):126-41.Texto completo  Resumo

65. Woolf AD, Goldman R, Bellinger DC. Update on the clinical management of childhood lead poisoning. Pediatr Clin North Am. 2007 Apr;54(2):271-94. Resumo

66. Sandoval C, Jayabose S, Eden AN. Trends in diagnosis and management of iron deficiency during infancy and early childhood. Hematol Oncol Clin North Am. 2004 Dec;18(6):1423-38. Resumo

67. Wattendorf DJ, Muenke M. Fetal alcohol spectrum disorders. Am Fam Physician. 2005 Jul 15;72(2):279-82;285. Resumo

68. Sokol RJ, Martier SS, Ager JW. The T-ACE questions: practical prenatal detection of risk-drinking. Am J Obstet Gynecol. 1989 Apr;160(4):863-8. Resumo

69. Kaufman DM. Congenital cerebral impairments. In: Kaufman DM. Clinical neurology for psychiatrists. 6th ed. Bronx, NY: Elsevier; 2007:295-311.

70. McKeown NJ, Tews MC, Gossain VV, et al. Hyperthyroidism. Emerg Med Clin North Am. 2005 Aug;23(3):669-85, viii. Resumo

71. Meltzer LJ. Mindell JA. Sleep and sleep disorders in children and adolescents. Psychiatr Clin North Am. 2006 Dec;29(4):1059-76. Resumo

72. Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019 Oct;144(4):e20192528.Texto completo  Resumo

73. Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. V: scales assessing attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2003 Sep;42(9):1015-37. Resumo

74. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. Sep 2019 [internet publication].Texto completo

75. Ghuman JK, Arnold LE, Anthony BJ. Psychopharmacological and other treatments in preschool children with attention-deficit/hyperactivity disorder: current evidence and practice. J Child Adolesc Psychopharmacol. 2008 Oct;18(5):413-47. Resumo

76. Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol. 2004 Jan;14(1):11-28. Resumo

77. Garfield CF, Dorsey ER, Zhu S, et al. Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010. Acad Pediatr. 2012 Mar-Apr;12(2):110-6. Resumo

78. Visser SN, Bitsko RH, Danielson ML, et al. Treatment of attention deficit/hyperactivity disorder among children with special health care needs. J Pediatr. 2015 Jun;166(6):1423-30. Resumo

79. National Institute for Health and Care Excellence. Clinical knowledge summaries. Scenario: management of attention deficit hyperactivity disorder (ADHD). Jan 2021 [internet publication].Texto completo

80. Santosh P. Stimulant medication to treat attention-deficit/hyperactivity disorder. BMJ. 2017 Jul 14;358:j2945. Resumo

81. Punja S, Shamseer L, Hartling L, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2016 Feb 4;(2):CD009996.Texto completo  Resumo

82. Storebø OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015 Nov 25;(11):CD009885.Texto completo  Resumo

83. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018 Sep;5(9):727-38.Texto completo  Resumo

84. Storebø OJ, Pedersen N, Ramstad E, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Cochrane Database Syst Rev. 2018 May 9;(5):CD012069.Texto completo  Resumo

85. Moran LV, Ongur D, Hsu J, et al. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019 Mar 21;380(12):1128-38.Texto completo  Resumo

86. Hollis C, Chen Q, Chang Z, et al. Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study. Lancet Psychiatry. 2019 Aug;6(8):651-8.Texto completo  Resumo

87. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999 Dec:56(12):1073-86.Texto completo  Resumo

88. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit hyperactivity disorder. Pediatrics. 2004 Apr;113(4):754-61. Resumo

89. Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):989-1002. Resumo

90. Brams M, Moon E, Pucci M, et al. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. Curr Med Res Opin. 2010 Aug;26(8):1809-25. Resumo

91. Faraone SV, Glatt SJ, Bukstein OG, et al. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J Atten Disord. 2009 Jan;12(4):308-15. Resumo

92. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010 Jan;19(4):353-64. Resumo

93. Arnold LE. Methylphenidate vs. amphetamine: a comparative review. J Atten Disord. 2000 Jan;3(4):200-11.Texto completo

94. Cheng JY, Chen RY, Ko JS, et al. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents: meta-analysis and meta-regression analysis. Psychopharmacology (Berl). 2007 Oct;194(2):197-209. Resumo

95. Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2018 Jun 26;(6):CD007990.Texto completo  Resumo

96. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002 Jul;41(7):776-84. Resumo

97. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with ADHD: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001 Nov;108(5):E83.Texto completo  Resumo

98. Buitelaar J, Michelson D, Danckaerts M, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry. 2007 Mar 1;61(5):694-9. Resumo

99. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002 Dec;63(12):1140-7. Resumo

100. Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry. 2007 Mar;41(3):222-30. Resumo

101. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008 Jun;165(6):721-30.Texto completo  Resumo

102. Scott NG, Ripperger-Suhler J, Rajab MH, et al. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2010 Jun;20(3):197-203. Resumo

103. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007 Sep;46(9):1119-27. Resumo

104. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: clinical and research information on drug-induced liver injury. Atomoxetine. Jul 2017 [internet publication].Texto completo

105. Banaschewski T, Roessner V, Dittman RW, et al. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry. 2004;13(suppl 1):I102-16. Resumo

106. Rains A, Scahill L, Hamrin V. Nonstimulant medications for the treatment of ADHD. J Child Adolesc Psychiatr Nurs. 2006 Feb;19(1):44-7. Resumo

107. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008 Jan;121(1):e73-84. Resumo

108. Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012 Jan;51(1):74-85. Resumo

109. Sallee F, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009 Feb;48(2):155-65. Resumo

110. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010 Sep;24(9):755-68. Resumo

111. Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011 Jun;127(6):e1406-13. Resumo

112. Croxtall JD. Clonidine extended-release: in attention-deficit hyperactivity disorder. Paediatr Drugs. 2011 Oct 1;13(5):329-36. Resumo

113. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996 Oct;35(10);1314-21. Resumo

114. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry. 2005 Apr 1;57(7):793-801. Resumo

115. Biederman J, Spencer T. Non-stimulant treatments for ADHD. Eur Child Adolesc Psychiatry. 2000;9(suppl 1):I51-9. Resumo

116. Biederman J, Baldessarini RJ, Wright V, et al. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. efficacy. J Am Acad Child Adolesc Psychiatry. 1989 Sep;28(5):777-84. Resumo

117. Loy JH, Merry SN, Hetrick SE, et al. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev. 2017 Aug 9;(8):CD008559.Texto completo  Resumo

118. Ray WA, Stein CM, Murray KT, et al. Association of antipsychotic treatment with risk of unexpected death among children and youths. JAMA Psychiatry. 2019 Feb 1;76(2):162-71.Texto completo  Resumo

119. Langberg JM, Arnold LE, Flowers AM, et al. Parent-reported homework problems in the MTA study: evidence for sustained improvement with behavioral treatment. J Clin Child Adolesc Psychol. 2010;39(2):220-33. Resumo

120. Jones K, Daley D, Hutchings J, et al. Efficacy of the Incredible Years Programme as an early intervention for children with conduct problems and ADHD: long-term follow-up. Child Care Health Dev. 2008 May;34(3):380-90. Resumo

121. Chan E, Fogler JM, Hammerness PG. Treatment of attention-deficit/hyperactivity disorder in adolescents: a systematic review. JAMA. 2016 May 10;315(18):1997-2008. Resumo

122. Storebø OJ, Elmose Andersen M, Skoog M, et al. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev. 2019 Jun 21;(6):CD008223.Texto completo  Resumo

123. Asarnow JR, Rozenman M, Wiblin J, et al. Integrated medical-behavioral care compared with usual primary care for child and adolescent behavioral health: a meta-analysis. JAMA Pediatr. 2015 Oct;169(10):929-37.Texto completo  Resumo

124. Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1284-1293. [Erratum in: Am Acad Child Adolesc Psychiatry. 2007;46:141.] Resumo

125. Greenhill LL, Posner K, Vaughan BS, et al. Attention deficit hyperactivity disorder in preschool children. Child Adolesc Psychiatr Clin N Am. 2008 Apr;17(2):347-66, ix. Resumo

126. Harstad E, Shults J, Barbaresi W, et al. α2-adrenergic agonists or stimulants for preschool-age children with attention-deficit/hyperactivity disorder. JAMA. 2021 May 25;325(20):2067-75. Resumo

127. Chen Q, Sjölander A, Runeson B, et al. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ. 2014 Jun 18;348:g3769.Texto completo  Resumo

128. Man KK, Coghill D, Chan EW, et al. Association of risk of suicide attempts with methylphenidate treatment. JAMA Psychiatry. 2017 Oct 1;74(10):1048-55. Resumo

129. Cagigal C, Silva T, Jesus M, et al. Does diet affect the symptoms of ADHD? Curr Pharm Biotechnol. 2019;20(2):130-6. Resumo

130. Evans S, Ling M, Hill B, et al. Systematic review of meditation-based interventions for children with ADHD. Eur Child Adolesc Psychiatry. 2018 Jan;27(1):9-27. Resumo

131. Karpouzis F, Bonello R, Pollard H. Chiropractic care for paediatric and adolescent attention-deficit/hyperactivity disorder: a systematic review. Chiropr Osteopat. 2010 Jun 2;18:13.Texto completo  Resumo

132. American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001 Oct;108(4):1033-44.Texto completo  Resumo

133. Wilens T, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults who divert or misuse their prescribed medication. J Am Acad Child Adolesc Psychiatry. 2006 Apr;45(4):408-14. Resumo

134. Sumner C, Sher L, Sutton V, et al. Atomoxetine treatment for pediatric patients with ADHD and comorbid anxiety - congress abstract TP74. Paper presented at: 10th International Child Neurology Congress (ICNC). 2006. Montreal, Canada. Neuropediatrics. 2006;37(S1):TP74.Texto completo

135. Otasowie J, Castells X, Ehimare UP, et al. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2014;(9):CD006997.Texto completo  Resumo

136. Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002 Feb 26;58(4):527-36. Resumo

137. ClinicalTrials.gov. KP415 classroom study in children (6-12 years of age) with ADHD. NCT03292952. Jun 2020 [internet publication].Texto completo

138. Nasser A, Liranso T, Adewole T, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021 Apr;43(4):684-700.Texto completo  Resumo

139. Nasser A, Liranso T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020 Aug;42(8):1452-66.Texto completo  Resumo

140. Nasser A, Kosheleff AR, Hull JT, et al. Translating attention-deficit/hyperactivity disorder rating scale-5 and Weiss functional impairment rating scale-parent effectiveness scores into clinical global impressions clinical significance levels in four randomized clinical trials of SPN-812 (viloxazine extended-release) in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2021 Apr;31(3):214-26.Texto completo  Resumo

141. McGough JJ, Sturm A, Cowen J, et al. Double-blind, sham-controlled, pilot study of trigeminal nerve stimulation for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2019 Apr;58(4):403-11.e3.Texto completo  Resumo

142. Barkley RA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: I. an 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990 Jul;29(4):546-57. Resumo

143. Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of ADHD and related disorders. Arch Gen Psychiatry. 1996 May;53(5):437-46. Resumo

144. Curry AE, Yerys BE, Metzger KB, et al. Traffic crashes, violations, and suspensions among young drivers with ADHD. Pediatrics. 2019 Jun;143(6):e20182305.Texto completo  Resumo

145. Barkley RA, Fischer M, Smallish L, et al. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry. 2004 Feb;45(2):195-211. Resumo

146. Barkley RA, Fischer M, Smallish L, et al. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adoles Pscyhiatry. 2006 Feb;45(2):192-202. Resumo

147. Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol. 2004 Feb;14(2):65-73. Resumo

148. Kidwell KM, Van Dyk TR, Lundahl A, et al. Stimulant medications and sleep for youth with ADHD: a meta-analysis. Pediatrics. 2015 Dec;136(6):1144-53.Texto completo  Resumo

149. Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child. 2005 Aug;90(8):801-6. Resumo

150. Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):1015-27. Resumo

151. Spencer TJ, Biederman J, Harding M, et al. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry. 1996 Nov;35(11):1460-9. Resumo

152. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006 Apr 6;354(14):1445-8.Texto completo  Resumo

153. Hammerness PG, Perrin JM, Shelley-Abrahamson R, et al. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry. 2011 Oct;50(10):978-90. Resumo

154. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011 Nov 17;365(20):1896-904. Resumo

155. Shin JY, Roughead EE, Park BJ, et al. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ. 2016 May 31;353:i2550.Texto completo  Resumo

156. Wilens TE, Spencer TJ, Swanson JM, et al. Combining methylphenidate and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry. 1999 May;38(5):614-9. Resumo

157. Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, placebo-controlled, parallel-group study of SL1381 (Adderall XR) in children with attention-deficit hyperactivity disorder. Pediatrics. 2002 Aug;110(2 Pt 1):258-66. Resumo

158. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit hyperactivity disorder. Pediatrics. 2001 Oct;108(4):883-92. Resumo

159. Gadow KD, Sverd J, Sprafkin J, et al. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry. 1999 Apr;56(4):330-6.Texto completo  Resumo

160. Gadow KD, Sverd J. Stimulants for ADHD in child patients with Tourette's syndrome: the issue of relative risk. J Dev Behav Pediatr. 1990 Oct;11(5):269-71. Resumo

161. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003 Jan;111(1):179-85. Resumo

162. Wilens TE, Morrison NR. The intersection of attention-deficit/hyperactivity disorder and substance abuse. Curr Opin Psychiatry. 2011 Jul;24(4):280-5. Resumo

163. Winhusen TM, Lewis DF, Riggs PD, et al. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011 Oct;21(5):455-63. Resumo

164. Schoenfelder EN, Faraone SV, Kollins SH. Stimulant treatment of ADHD and cigarette smoking: a meta-analysis. Pediatrics. 2014 Jun;133(6):1070-80.Texto completo  Resumo

165. Vitiello B, Elliott GR, Swanson JM, et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry. 2012 Feb;169(2):167-77.Texto completo  Resumo

166. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder. Circulation. 2008 May 6;117(18):2407-23.Texto completo  Resumo

167. Rashid MA, Lovick S, Llanwarne NR. Medication-taking experiences in attention deficit hyperactivity disorder: a systematic review. Fam Pract. 2018 Mar 27;35(2):142-50.Texto completo  Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal